Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 94% Improvement Relative Risk Recovery 38% Hospitalization time 45% c19early.org/t Saber-Moghaddam et al. Curcumin for COVID-19 EARLY Is early treatment with curcumin beneficial for COVID-19? Prospective study of 41 patients in Iran Lower progression (p=0.0013) and improved recovery (p=0.043) Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 Favors curcumin Favors control
Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004
Saber-Moghaddam et al., Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19.., Phytotherapy Research, doi:10.1002/ptr.7004
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
risk of progression, 94.3% lower, RR 0.06, p = 0.001, treatment 0 of 21 (0.0%), control 8 of 20 (40.0%), NNT 2.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no recovery, 38.4% lower, RR 0.62, p = 0.04, treatment 11 of 21 (52.4%), control 17 of 20 (85.0%), NNT 3.1.
hospitalization time, 44.8% lower, relative time 0.55, p < 0.001, treatment 21, control 20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saber-Moghaddam et al., 3 Jan 2021, prospective, Iran, peer-reviewed, 9 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: Received: 18 August 2020 Revised: 14 December 2020 Accepted: 14 December 2020 DOI: 10.1002/ptr.7004 RESEARCH ARTICLE Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial Niloofar Saber-Moghaddam1 | Soofia Salari1 | Sepideh Hejazi2 | | Saeed Eslami5 | Seyed Mahdi Rezayat6 Zhila Taherzadeh4 Mahmoud Reza Jaafari7,8 | Sepideh Elyasi1 Mahnaz Amini3 | | 1 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 2 Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 3 Curcumin is proposed as a potential treatment option for coronavirus disease-19 (COVID-19) by inhibiting the virus entrance, encapsulation and replication, and modulating various cellular signaling pathways. In this open-label nonrandomized clinical trial, efficacy of nano-curcumin oral formulation has been evaluated in hospitalized Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran patients with mild–moderate COVID-19. Forty-one patients who fulfilled the inclu- 4 sion criteria were allocated to nano-curcumin (n = 21) group (Sinacurcumin soft gel, Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 5 Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran contains 40 mg curcuminoids as nanomicelles, two capsules twice a day) or control (n = 20) group, for 2 weeks. Patients' symptoms and laboratory data were assessed at baseline and during follow-up period. Most of symptoms including fever and chills, tachypnea, myalgia, and cough resolved significantly faster in curcumin group. More- 6 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran 7 over, SaO2 was significantly higher in treatment group after 2, 4, 7, and 14 days of follow-up and lymphocyte count after 7 and 14 days. Duration of supplemental O2 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran use and hospitalization was also meaningfully shorter in treatment group. It is also 8 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran of infection during follow-up period, but it occurred in 40% of control group. Oral Correspondence Sepideh Elyasi, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Email: elyasis@mums.ac.ir noteworthy to mention that no patient in treatment group experienced deterioration curcumin nano-formulation can significantly improve recovery time in hospitalized COVID-19 patients. Further randomized placebo controlled trials with larger sample size are recommended. KEYWORDS antiinflammatory, clinical response, COVID-19, curcumin Funding information Research Council of Mashhad University of Medical Sciences 1 | I N T RO DU CT I O N cause of COVID-19 mortality, mostly due to cytokine storm syndrome (Mehta et al., 2020; Ruan, Yang, Wang, Jiang, & Song, 2020). Actually, Coronavirus disease 2019 (COVID-19)-induced pneumonia became high cytokine level including IL-2, IL-7, granulocyte colony–stimulating an international concern, which led to the first pandemic of the..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit